Top Stories
BMS and J&J's oral Factor XIa inhibitor did not increase the incidence of intracranial or fatal bleeding.
Mimrylo (rusfertide) achieved a 76.9% response rate in patients with polycythemia vera (PV) in the Phase III VERIFY trial.
The GLP-1/GIP dual agonist was approved to lower the risk of major adverse cardiovascular events in patients with type 2 diabetes.
The stalking-horse bid, which includes an upfront payment of $57.5 million, would give Teva worldwide rights to assets including agitation treatment Igalmi.
A data safety monitoring board found there was a "numerical imbalance" in overall survival between patients receiving autogene cevumeran and those who did not.
Conference News
Takeda has crossed the finish line in bringing a new mechanism to polycythemia vera (PV), but its work is far from over. Getting physicians to break from a treatment algorithm that seems etched in stone may prove to be an even longer haul.
Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular diseaseNewswise — (Munich, Germany – August 29, 2026) - The investig...
First-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction in patients with acute MI undergoing PCI, with more than 80% reaching the guideli...
Pacibekitug, a novel, long-acting monoclonal antibody that targets interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease (CKD) and at high inflam...
Vericiguat did not improve peripheral vasodilator function or anginal symptoms in patients with angina and no obstructive coronary arteries (ANOCA) and with epicardial and/or microvascular vasospasm. ...
